A Grey Literature Current Awareness Tool in Cancer Care
MORE INFORMATION
▼
Wednesday, 30 July 2014
European Medicines Agency Recommends Granting a Marketing Authorisation for Ibrutinib
On 24 July 2014, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ibrutinib (Imbruvica) 140 mg hard capsule intended for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL). Read more here
No comments:
Post a Comment